For instance, semaglutide has been approved and is being researched for indications including obesity, T2DM, reducing cardiovascular risk, chronic kidney disease, NAFLD, and AD, indicating that the development of new indications could provide new growth opportunities for GLP-1 drugs
See more News 6 Mar 2024 Putting GA4GH standards into practice: Mallory Freeberg and Alastair Thomson to lead GA4GH Implementation Forum See more News 21 Feb 2024 Supporting alignment across GA4GH standards: TASC seeks feedback on new pagination guide See more News 20 Feb 2024 Grand challenges in rare diseases: register for the GA4GH Rare Disease Community of Interest webinar on 29 February 2024 See more News 14 Feb 2024 NIH and GA4GH commit to ongoing collaboration See more News 1 Feb 2024 GA4GH opens call for members of the new Strategic Leadership Committee See more News 8 Dec 2023 GA4GH Clinical & Phenotypic Data Capture Work Stream welcomes new Co-Lead Mnica Muoz-Torres of the University of Colorado See more News 30 Nov 2023 Two leading standards bodies launch Neuroscience Community, powering a global data network that will speed up answers in autism, Parkinsons, addiction, and more See more News 16 Nov 2023 Want to help shape guidelines for pandemic prep, schema consensus, sequencing metadata, and categorical variants
We examined the characteristics and outcomes of stroke patients admitted from LTC nationally and how this changed during COVID19 pandemic
Although, high glucose consumption and metabolism in head and neck cancer is clinically relevant, since the uptake of (18)F-2-fluro-2-deoxy-D-glucose (FDG) has been significantly observed through PET/CT scans
